What one share of Allarity Therapeutics holds
We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform.
Allarity Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$0.79 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.88 |
| Cash and investments | $1.07 |
| Book value | $0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | $0.02 | −$0.78 | $0.00 | −$1.03 | — | $0.61 |
Common questions about Allarity Therapeutics
How much does one share of Allarity Therapeutics earn?
Over the last 12 months, Allarity Therapeutics lost $0.79 for each share on $0.02 of sales.
Does Allarity Therapeutics pay a dividend?
Allarity Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Allarity Therapeutics’s book value per share?
Allarity Therapeutics’s book value is $0.22 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Allarity Therapeutics have?
Each share of Allarity Therapeutics has $1.07 of cash and investments, as of June 30, 2026.
What is Allarity Therapeutics’s free cash flow per share?
−$0.88 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.